In the crowded field of metabolic therapies, where GLP-1 agonists like semaglutide dominate obesity care, Hoth Therapeutics is betting on a different biological lever: glial cell line-derived neurotrophic factor (GDNF). New preclinical data from a Cooperative Research and Development Agreement (CRADA) with the VA suggests GDNF can reprogram liver fat metabolism by shutting down the fat-creation gene Srebf1 and activating fat-burning pathways via Pparα. In mouse models, this dual mechanism reportedly outperformed semaglutide, hinting at a potential niche beyond current incretin-based drugs. For Hoth, a micro-cap firm with a market value of $10 million, this represents a high-risk pivot into metabolic disease, far from its core dermatology pipeline.
Science: Targeting liver fat at the gene level
GDNF, traditionally studied for neurodegenerative diseases, appears to modulate key regulators of lipid homeostasis. The CRADA data, published via PRNewswire on April 13, 2026, shows statistically significant reductions in Srebf1 (sterol regulatory element-binding transcription factor 1), which drives fatty acid synthesis, and increases in Pparα (peroxisome proliferator-activated receptor alpha), which promotes fatty acid oxidation. This dual-gene approach could address metabolic dysfunction-associated fatty liver disease (MAFLD) by directly altering hepatic fat storage and utilization, contrasting with GLP-1s that primarily reduce appetite and glucose. However, the mechanism's translation to humans remains unproven, and Hoth has not disclosed formulation or delivery plans for systemic use.
Trial context and competitive landscape
Hoth's clinical pipeline centers on BioLexa for atopic dermatitis, currently in Phase 2, with no active trials listed for GDNF in metabolic indications. The CRADA data is preclinical, lacking patient populations or endpoints, and any Phase 1 study would likely take years to initiate. In MAFLD and obesity, competitors include Novo Nordisk's semaglutide (approved for obesity, in Phase 3 for NASH), Madrigal Pharmaceuticals' resmetirom (approved for NASH), and Lilly's tirzepatide (in late-stage trials for NASH). GDNF's novel mechanism could complement these therapies if proven safe, but Hoth's micro-cap status and focus on dermatology raise questions about its ability to fund costly metabolic trials.
GDNF's outperformance of semaglutide in models is intriguing, but preclinical success in metabolic disease rarely predicts clinical outcomes—especially for a company with no prior experience in this space.
For patients with MAFLD, where approved therapies are limited, GDNF offers a theoretical path to address liver fat directly, but any benefit is speculative. Investors should note Hoth's stock closed at $0.52, down 4.44%, reflecting skepticism amid thin liquidity. The implications hinge on whether Hoth can advance GDNF beyond preclinical hype—likely requiring partnerships or capital infusions it currently lacks. In a sector where biologic mechanisms face high attrition, this data is a footnote until human trials begin.
